NCT01869491

Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study

A Multi-centre, Randomised, Double-blind, Two Arm, Parallel Group, Placebo-controlled Study to Assess the Effect of Compound Sodium Alginate Double Action Chewable Tablets in Patients With Gastro-esophageal Reflux Disease

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,107 (actual)
• Sponsor: Reckitt Benckiser Healthcare (UK) Limited · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study is being conducted to provide evidence that Compound Sodium Alginate Double Action Chewable Tablets are effective in managing the symptoms of heartburn, acid regurgitation and dyspepsia in patients with Gastroesophageal Reflux Disease (GERD).

Conditions

• Gastroesophageal Reflux Disease
• Dyspepsia

Interventions

Type	Name	Description
DRUG	Compound Sodium Alginate Double Action Chewable Tablets	2 tablets four times daily
DRUG	Matching placebo tablets	2 tablets four times daily

Timeline

• Start date: 2013-06-05
• Primary completion: 2014-05-01
• Completion: 2014-05-01
• First posted: 2013-06-05
• Last updated: 2025-05-08
• Results posted: 2025-03-13

Locations

2 sites across 1 country: China